Oropouche Virus: A Neglected Global Arboviral Threat.

Oropouche virus epidemiology evolutionary immunity structure vaccine development

Journal

Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979

Informations de publication

Date de publication:
13 Jan 2024
Historique:
received: 12 11 2023
revised: 02 01 2024
accepted: 12 01 2024
medline: 16 1 2024
pubmed: 16 1 2024
entrez: 15 1 2024
Statut: aheadofprint

Résumé

The Oropouche virus is an important arthropod-borne virus in the Peribunyaviridae family that can cause febrile illnesses, and it is widely distributed in tropical regions such as Central and South America. Since the virus was first identified, a large number of related cases are reported every year. No deaths have been reported to date, however, the virus can cause systemic infections, including the nervous and blood systems, leading to serious complications. The transmission of Oropouche virus occurs through both urban and sylvatic cycles, with the anthropophilic biting midge Culicoides paraensis serving as the primary vector in urban areas. Direct human-to-human transmission of Oropouche virus has not been observed. Oropouche virus consists of three segments, and the proteins encoded by the different segments enables the virus to replicate efficiently in the host and to resist the host's immune response. Phylogenetic analyses showed that Oropouche virus sequences are geographically distinct and have closer homologies with Iquitos virus and Perdoes virus, which belong to the family Peribunyaviridae. Despite the enormous threat it poses to public health, there are currently no licensed vaccines or specific antiviral treatments for the disease it causes. Recent studies have utilised imJatobal virusmunoinformatics approaches to develop epitope-based peptide vaccines, which have laid the groundwork for the clinical use of vaccines. The present review focuses on the structure, epidemiology, immunity and phylogeny of Oropouche virus, as well as the progress of vaccine development, thereby attracting wider attention and research, particularly with regard to potential vaccine programs.

Identifiants

pubmed: 38224842
pii: S0168-1702(24)00011-X
doi: 10.1016/j.virusres.2024.199318
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

199318

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yuli Zhang (Y)

WeiFang Medical University, Weifang, 261053, China.

Xiao Liu (X)

WeiFang Medical University, Weifang, 261053, China.

Zhen Wu (Z)

WeiFang Medical University, Weifang, 261053, China.

Shuo Feng (S)

WeiFang Medical University, Weifang, 261053, China.

Ke Lu (K)

WeiFang Medical University, Weifang, 261053, China.

Wenbing Zhu (W)

WeiFang Medical University, Weifang, 261053, China.

Hengyi Sun (H)

WeiFang Medical University, Weifang, 261053, China. Electronic address: Sunhengyi1987@wfmc.edu.cn.

Guoyu Niu (G)

WeiFang Medical University, Weifang, 261053, China. Electronic address: niugy@wfmc.edu.cn.

Classifications MeSH